Semaglutide, a GLP-1 agonist, has been widely studied due to its versatility, efficacy, and ability to address multiple ...

A SYSTEMATIC review investigating the impact of glucagon-like peptide-1 receptor agonists on alcohol consumption has yielded ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Under Secretary for Health Dr. Shereef Elnahal said Monday the VA needs extra funding to cover the costs of drugs such as ...

Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $35 ...

Takers of GLP-1 are reportedly going on a "holiday pause" to enjoy meal centric family celebrations. Here, an MD breaks down ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

A new study suggests that 40% of American adults have conditions that could benefit from semaglutide treatment.

In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...